A number of publications have indicated that gamma secretase inhibition can boost the expression of a cancer marker called BCMA on the surface of cancer cells, particularly in multiple myeloma and this increases cancer cell susceptibility to BCMA-specific chimeric antigen receptor (CAR) T cell immunotherapy and subsequent tumour suppression [293]. Here, TNFRSF17 is linked to AL amyloidosis.